| Literature DB >> 15144874 |
Ronen R Leker1, Michal Aharonowiz, Nigel H Greig, Haim Ovadia.
Abstract
No neuroprotective compounds are clinically available for the treatment of ischemic stroke. The potential salutary effect of pifithrin alpha, a novel-specific inhibitor of the transcription factor p53, administered 1-6 h following focal reversible cerebral ischemia, was investigated. Studies measuring histological, motor, and behavioral outcomes showed significant improvements in pifithrin alpha-treated animals. Pifithrin alpha reduced the number of apoptotic cells in the ischemic brain by inhibiting the binding of p53 to its DNA sites as it reduced the expression of the p53-related gene p21(WAF) without changing the amount of p53 protein itself.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15144874 DOI： 10.1016/j.expneurol.2004.01.030
Source DB: PubMed Journal: Exp Neurol ISSN： 0014-4886 Impact factor: 5.330